Microgenics DRI® Oxycodone Assay Now Has Application for Olympus Analyzers
Orlando, FL, July 26, 2005 - Olympus has developed applications for the new DRI® Oxycodone assay on its chemistry-immuno analyzers, in conjunction with the assay's recent introduction by Microgenics Corporation, Fremont, CA. The assay has applications for the entire Olympus AU® chemistry-immuno analyzer system platform, including the AU400/400e®, AU600®, AU640/640e®, AU2700® and AU5400® chemistry-immuno analyzers.
The Oxycodone assay is NAD-G6PDH based, and can be read bichromatically at 340/410 nm. Results can be determined as qualitative (pass/fail) at cutoffs of 100 ng/mL or 300 ng/mL. They can also be determined semi-quantitatively up to 1000 ng/mL.
The DRI Oxycodone Assay is used to measure Oxycodone in urine. Oxycodone is a potent pain medication and a nervous system depressant sold under the trade names OxyContin®, Percodan®, and Percocet®, among others.
For additional information about the DRI Oxycodone assay for use on Olympus analyzers, contact Carole Dauscher, Product Manager, Olympus Diagnostic Systems Group, at 1-800-223-0125 x5654 or email: email@example.com.
About Olympus Diagnostic Systems Group
Olympus Diagnostic Systems Group provides innovative solutions that meet the high productivity demands of hospitals, integrated healthcare delivery networks, reference labs, blood banks and pharmaceutical labs. Olympus offers the broadest standardized line of random access chemistry-immuno analyzers, along with lab automation systems, comprehensive patient safety systems, blood bank analyzers and reagents. Olympus solutions save laboratories time, enhance patient safety, maximize productivity, and deliver fast, reliable results.
Olympus is a precision technology leader, designing and delivering innovative solutions in healthcare and consumer electronics worldwide.
Olympus works collaboratively with its customers and its parent company, Tokyo-based Olympus Corporation, to leverage R&D investment in precision technology and manufacturing processes across diverse business lines. These include:
- Gastrointestinal endoscopes, accessories, and minimally invasive surgical products;
- Advanced clinical and research microscopes;
- Lab automation systems, chemistry-immuno and blood bank analyzers and reagents; and
- Digital and film cameras, and digital voice recorders.
In the U. S. and Canada, Olympus serves healthcare, scientific and commercial laboratory markets with integrated product solutions and financial, educational and consulting services that help customers efficiently, reliably, safely, and easily achieve superior results. Olympus is the leader in gastrointestinal endoscopy and clinical and educational microscopes. The company's market-leading consumer electronics business spans North and South America. For more information, visit www.olympusamerica.com.